Has Cesar Rodriguez Valdes, MD received payments from drug or device companies?

Yes. Drug and device makers reported $312,879 in general payments to Cesar Rodriguez Valdes, MD across 283 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Cesar Rodriguez Valdes, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Cesar Rodriguez Valdes, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Cesar Rodriguez Valdes, MD

Medical Oncology · New York, NYNPI 1518178805

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (45.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 20.4%. Among medical oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$312,879in general payments, 2019–2025

Across 283 payments — averaging $1105.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$64K
Bristol Myers Squibb$44K
E.r. Squibb & Sons, L.L.C.$37K
Takeda Pharmaceuticals U.S.A., Inc.$36K
Sanofi$35K
Janssen Research & Development, LLC$27K
plus $70K from 15 others

$3,193,372in research payments, 2019–2025

Across 197 payments — averaging $16,210 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Amgen$1.4M
AbbVie$1.3M
Janssen Research & Development, LLC$276K
E.r. Squibb & Sons, L.L.C.$85K
Bristol Myers Squibb$50K
Modernatx, Inc.$31K
plus $37K from 3 others

What the payments were for

Consulting fees$133,48943%
Speaking & faculty fees$141,46045%
Grants$2990%
Travel & lodging$28,4319%
Food & beverage$9,2003%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	75	$63,842
Bristol Myers Squibb	32	$43,804
E.r. Squibb & Sons, L.L.C.	23	$37,124
Takeda Pharmaceuticals U.S.A., Inc.	24	$35,970
Sanofi	37	$35,280
Janssen Research & Development, LLC	9	$27,271
Pfizer	13	$15,878
Janssen Global Services, LLC	16	$13,642
Janssen Scientific Affairs, LLC	17	$13,110
Regeneron Healthcare Solutions, Inc.	5	$9,024
AbbVie	4	$7,467
Sanofi-aventis U.S. LLC	2	$4,180
GSK	2	$1,956
Amgen	7	$1,956
Legend Biotech USA Inc.	6	$1,576
Karyopharm Therapeutics Inc.	3	$270
Adaptive Biotechnologies Corporation	2	$190
Genentech, Inc.	2	$139
Seagen Inc.	2	$133
AstraZeneca	1	$38
Esperion Therapeutics, Inc.	1	$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DARZALEX$58,737
TECVAYLI$37,519
CARVYKTI$32,333
SARCLISA$25,363
Revlimid$18,121
ELREXFIO$15,783
NINLARO$12,369
ABECMA$11,878
RYBREVANT$9,801
LYNOZYFIC$9,009
TALVEY$7,990
THYMOGLOBULIN$4,080
Kyprolis$1,802
Pomalyst$836
XPOVIO$150

How this compares

$312,879 in reported general payments places this provider in the 95th percentile of 498 medical oncology providers in New York.

See all medical oncology providers in New York →

Medicare billing

Part B allowed, 2024

$76,436

Medicare patients

155

Services billed

538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Entecavir	11	$5,801
Acyclovir	34	$259

Paid to pharmacies, not to this prescriber.

Other medical oncology in New York

Craig ThompsonNew York$4.8M
Andrew SeidmanNew York$1.3M
Joshua RichterNew York$971K
Edward GelmannNew York$944K
Ghassan Abou-AlfaNew York$825K
Miguel PeralesNew York$769K
Komal JhaveriNew York$642K
Joshua BrodyNew York$492K
Aiwu HeNew York$445K
Raajit RampalNew York$418K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →